In this book, the authors present the history of generic drug development, FDA and European Medecines Agency (EMA) requirements for generic drug entry, a comparison of generic and branded drugs, concerns around generic ophthalmic drugs, the issues of costs of generic and branded drugs, and issues as well as perceptions regarding the clinical use and acceptance of generic drugs among the patients, prescribers, and pharmacists. In addition to the previous edition, a chapter has been added about biosimilars.